<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1046</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2008-4-1-55</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Use of zoledronic acid reduces a long-term risk for skeletal complications in patients with cancer of the kidney or urinary bladder</article-title><trans-title-group xml:lang="ru"><trans-title>Назначение золедроновой кислоты снижает долгосрочный риск развития скелетных осложнений у больных раком почки или мочевого пузыря</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mulders</surname><given-names>P. F.</given-names></name><address><country country="NL">Netherlands</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>K.</given-names></name><address><country country="DE">Germany</country></address><bio><p>Berlin</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Tchekmedyian</surname><given-names>N. S.</given-names></name><address><country country="US">United States</country></address><bio><p>Long Beach</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff id="aff1"><institution>University Hospital Nijmegen</institution></aff><aff id="aff2"><institution>Universitatsklinikum Benjamin Franklin</institution></aff><aff id="aff3"><institution>Pacific Shores Medical Group</institution></aff><pub-date date-type="pub" iso-8601-date="2008-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2008</year></pub-date><volume>4</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2020-02-13"><day>13</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-13"><day>13</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1046">https://oncourology.abvpress.ru/oncur/article/view/1046</self-uri><abstract xml:lang="en"><p>.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list/></back></article>
